On September 5, 2019, the CNIPA issued the Request for Invalidation No. 41183, declaring that all rights of invention patent 201610203379.5, named “an anti-cancer injection and its application” of Li Xueping were invalid.

On January 11, 2019, the CNIPA authorized the announcement of the above patents. Since then, the patent attracted the attention of media and had been widely reported. The patent claimed that the saline in certain concentration (about 9%) can be used to treat cancer, which was quite different from conventional professional cognation because normally the concentration of saline for injection is around 0.9%. The above-mentioned patent and the CNIPA that made the authorization had been widely discussed.

On February 27, 2019, the team of Hengbo accepted the client's entrustment and filed a request for invalidation of the above patents in the form of scarecrow. After nearly seven months of trial, the CNIPA finally made a decision to declare all rights of the patents were invalid.

According to the law, if the claimant disagrees with the invalidation decision, he or she can file an administrative litigation to the Beijing Intellectual Property Court within 3 months.